<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p107" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_107{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_107{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_107{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_107{left:341px;bottom:30px;}
#t5_107{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_107{left:377px;bottom:30px;}
#t7_107{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_107{left:540px;bottom:30px;}
#t9_107{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_107{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#tb_107{left:44px;bottom:63px;letter-spacing:0.1px;}
#tc_107{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_107{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_107{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_107{left:1118px;bottom:47px;letter-spacing:0.32px;}
#tg_107{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_107{left:36px;bottom:746px;letter-spacing:-0.17px;word-spacing:0.08px;}
#ti_107{left:41px;bottom:728px;}
#tj_107{left:58px;bottom:728px;letter-spacing:-0.09px;}
#tk_107{left:41px;bottom:709px;}
#tl_107{left:58px;bottom:709px;letter-spacing:-0.1px;word-spacing:0.01px;}
#tm_107{left:58px;bottom:691px;letter-spacing:-0.09px;}
#tn_107{left:58px;bottom:673px;letter-spacing:-0.09px;}
#to_107{left:58px;bottom:654px;letter-spacing:-0.08px;}
#tp_107{left:41px;bottom:636px;}
#tq_107{left:58px;bottom:636px;letter-spacing:-0.11px;}
#tr_107{left:63px;bottom:618px;}
#ts_107{left:76px;bottom:618px;letter-spacing:-0.09px;}
#tt_107{left:246px;bottom:625px;letter-spacing:-0.14px;}
#tu_107{left:63px;bottom:600px;}
#tv_107{left:76px;bottom:600px;letter-spacing:-0.09px;}
#tw_107{left:63px;bottom:581px;}
#tx_107{left:76px;bottom:581px;letter-spacing:-0.09px;}
#ty_107{left:63px;bottom:563px;}
#tz_107{left:76px;bottom:563px;letter-spacing:-0.09px;}
#t10_107{left:237px;bottom:570px;}
#t11_107{left:250px;bottom:563px;letter-spacing:-0.09px;}
#t12_107{left:752px;bottom:570px;letter-spacing:-0.14px;}
#t13_107{left:63px;bottom:545px;}
#t14_107{left:76px;bottom:545px;letter-spacing:-0.09px;}
#t15_107{left:77px;bottom:526px;letter-spacing:-0.09px;}
#t16_107{left:275px;bottom:534px;letter-spacing:-0.13px;}
#t17_107{left:314px;bottom:526px;letter-spacing:-0.1px;}
#t18_107{left:41px;bottom:508px;}
#t19_107{left:58px;bottom:508px;letter-spacing:-0.09px;}
#t1a_107{left:58px;bottom:489px;letter-spacing:-0.09px;}
#t1b_107{left:41px;bottom:471px;}
#t1c_107{left:58px;bottom:471px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t1d_107{left:58px;bottom:453px;letter-spacing:-0.13px;word-spacing:0.04px;}
#t1e_107{left:962px;bottom:453px;letter-spacing:-0.1px;}
#t1f_107{left:58px;bottom:434px;letter-spacing:-0.1px;}
#t1g_107{left:188px;bottom:434px;letter-spacing:-0.06px;}
#t1h_107{left:36px;bottom:148px;}
#t1i_107{left:46px;bottom:142px;letter-spacing:0.12px;word-spacing:-0.05px;}
#t1j_107{left:45px;bottom:125px;letter-spacing:0.09px;}
#t1k_107{left:36px;bottom:114px;}
#t1l_107{left:46px;bottom:108px;letter-spacing:0.13px;}
#t1m_107{left:1091px;bottom:96px;letter-spacing:-0.11px;}
#t1n_107{left:420px;bottom:778px;letter-spacing:0.4px;word-spacing:-0.23px;}
#t1o_107{left:778px;bottom:786px;}
#t1p_107{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_107{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_107{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_107{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_107{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_107{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_107{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_107{font-size:17px;font-family:Webdings_k6;color:#000;}
.s7_107{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.s8_107{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_107{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sa_107{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sb_107{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.sc_107{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sd_107{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.se_107{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts107" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg107Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg107" style="-webkit-user-select: none;"><object width="1210" height="935" data="107/107.svg" type="image/svg+xml" id="pdf107" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_107" class="t s0_107">NCCN Guidelines Version 4.2024 </span>
<span id="t2_107" class="t s0_107">Head and Neck Cancers </span>
<span id="t3_107" class="t s1_107">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_107" class="t s2_107">® </span>
<span id="t5_107" class="t s1_107">(NCCN </span>
<span id="t6_107" class="t s2_107">® </span>
<span id="t7_107" class="t s1_107">), All rights reserved. NCCN Guidelines </span>
<span id="t8_107" class="t s2_107">® </span>
<span id="t9_107" class="t s1_107">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_107" class="t s3_107">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="tb_107" class="t s3_107">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="tc_107" class="t s4_107">NCCN Guidelines Index </span>
<span id="td_107" class="t s4_107">Table of Contents </span>
<span id="te_107" class="t s4_107">Discussion </span>
<span id="tf_107" class="t s5_107">RAD-A </span>
<span id="tg_107" class="t s5_107">3 OF 7 </span>
<span id="th_107" class="t s5_107">• Palliative 3D-CRT, IMRT, and Stereotactic Body RT (SBRT) </span>
<span id="ti_107" class="t s6_107"></span><span id="tj_107" class="t s5_107">Palliative radiation should be considered in the advanced cancer setting when curative-intent treatment is not appropriate. </span>
<span id="tk_107" class="t s6_107"></span><span id="tl_107" class="t s5_107">No general consensus exists for appropriate palliative RT regimens in head and neck cancer. For those who are either medically unsuitable </span>
<span id="tm_107" class="t s5_107">for standard RT or who have widely metastatic disease, palliative RT should be considered for relief or prevention of locoregional </span>
<span id="tn_107" class="t s5_107">symptoms if the RT toxicities are acceptable. RT regimens should be tailored individually; severe RT toxicities should be avoided when </span>
<span id="to_107" class="t s5_107">treatment is for palliation. </span>
<span id="tp_107" class="t s6_107"></span><span id="tq_107" class="t s5_107">Some recommended RT regimens include: </span>
<span id="tr_107" class="t s7_107">◊ </span><span id="ts_107" class="t s5_107">50 Gy in 20 fractions; </span>
<span id="tt_107" class="t s8_107">37 </span>
<span id="tu_107" class="t s7_107">◊ </span><span id="tv_107" class="t s5_107">37.5 Gy in 15 fractions (if well tolerated, consider adding 5 additional fractions to 50 Gy); </span>
<span id="tw_107" class="t s7_107">◊ </span><span id="tx_107" class="t s5_107">30 Gy in 10 fractions; </span>
<span id="ty_107" class="t s7_107">◊ </span><span id="tz_107" class="t s5_107">30 Gy in 5 fractions: </span>
<span id="t10_107" class="t s8_107">b </span>
<span id="t11_107" class="t s9_107">give 2 fractions/wk with ≥3 days between the 2 treatments; and </span>
<span id="t12_107" class="t s8_107">38 </span>
<span id="t13_107" class="t s7_107">◊ </span><span id="t14_107" class="t s5_107">44.4 Gy in 12 fractions, in 3 cycles (for each cycle, give 2 fractions 6 hours apart for 2 days in a row; treatments must exclude the spinal </span>
<span id="t15_107" class="t s5_107">cord after second cycle). </span>
<span id="t16_107" class="t s8_107">39,40 </span>
<span id="t17_107" class="t s5_107">Reassessment should be done at 1- to 3-week intervals. </span>
<span id="t18_107" class="t s6_107"></span><span id="t19_107" class="t s5_107">The use of shorter more hypofractionated treatment courses may be indicated, but the dose tolerance of the spinal cord and neural </span>
<span id="t1a_107" class="t s5_107">structures must be evaluated carefully in light of fraction size. </span>
<span id="t1b_107" class="t s6_107"></span><span id="t1c_107" class="t s5_107">Carefully evaluate the patient’s PS, treatment tolerance, tumor response, and/or any systemic progression. Other palliative/supportive care </span>
<span id="t1d_107" class="t s5_107">measures include analgesics, nutrition support, targeted therapy, immunotherapy, or chemotherapy, if indicated (</span><span id="t1e_107" class="t sa_107">NCCN Guidelines for </span>
<span id="t1f_107" class="t sa_107">Supportive Care</span><span id="t1g_107" class="t s5_107">). </span>
<span id="t1h_107" class="t sb_107">a </span>
<span id="t1i_107" class="t sc_107">For additional resources regarding the technical details of radiation, see the American College of Radiology Guidelines: </span>
<span id="t1j_107" class="t sd_107">https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards </span>
<span id="t1k_107" class="t sb_107">b </span>
<span id="t1l_107" class="t sc_107">For end-stage disease, patients can be given more hypofractionated schedules because of the very limited prognosis. </span>
<span id="t1m_107" class="t sa_107">Continued </span>
<span id="t1n_107" class="t s9_107">PRINCIPLES OF RADIATION TECHNIQUES </span>
<span id="t1o_107" class="t s8_107">a </span>
<span id="t1p_107" class="t se_107">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
